The following appendix lists the Publications from 2023, from the Velindre Cancer Service. This listing has been compiled by Velindre University NHS Trust’s Library Service.
During 2023, there has been a total of 143 publications – 79 articles and 64 conference abstracts.
Articles
A. Arana Echarri, L. Struszczak, M. Beresford, J. P. Campbell, R. H. Jones, D. Thompson and J. E. Turner (2023). "Immune cell status, cardiorespiratory fitness and body composition among breast cancer survivors and healthy women: a cross sectional study." Frontiers in Physiology 14: 1107070.
M. Coakley, G. Villacampa, P. Sritharan, C. Swift, K. Dunne, L. Kilburn, K. Goddard, C. Pipinikas, P. Rojas, W. Emmett, P. Hall, C. Harper-Wynne, T. Hickish, I. Macpherson, A. Okines, A. Wardley, D. Wheatley, S. Waters, C. Palmieri, M. Winter, R. J. Cutts, I. Garcia-Murillas, J. Bliss and N. C. Turner (2023). "Comparison of circulating tumor DNA assays for Molecular Residual Disease detection in early-stage triple negative breast cancer." Clinical cancer research : an official journal of the American Association for Cancer Research.
A. M. de Luna Aguilar, J. D. B. Fuentes, J. Ortega Anselmi, J. Olalla Inoa, P. Flores Navarro, A. Lopez de Sa, J. Fuentes Antras, C. Rodriguez Rey, A. Ortega Candil, F. Moreno Anton and J. A. Garcia Saenz (2023). "Clinical Experience with Abemaciclib in Patients Previously Treated with Another CDK 4/6 Inhibitor in a Tertiary Hospital: A Case Series Study." Cancers 15(18).
P. A. Henriksen, P. Hall, I. R. MacPherson, S. S. Joshi, T. Singh, M. Maclean, S. Lewis, A. Rodriguez, A. Fletcher, R. J. Everett, H. Stavert, A. Broom, L. Eddie, L. Primrose, H. McVicars, P. McKay, A. Borley, C. Rowntree, S. Lord, G. Collins, J. Radford, A. Guppy, M. C. Williams, A. Japp, J. R. Payne, D. E. Newby, N. L. Mills, O. Oikonomidou and N. N. Lang (2023). "Multicenter, Prospective, Randomized Controlled Trial of High-Sensitivity Cardiac Troponin I-Guided Combination Angiotensin Receptor Blockade and Beta-Blocker Therapy to Prevent Anthracycline Cardiotoxicity: The Cardiac CARE Trial." Circulation 148(21): 1680-1690.
A. J. Oswald, S. N. Symeonides, D. Wheatley, S. Chan, A. M. Brunt, K. McAdam, P. Schmid, S. Waters, C. Poole, C. Twelves, T. Perren, J. Bartlett, T. Piper, E. M. Chisholm, M. Welsh, R. Hill, L. E. M. Hopcroft, P. Barrett-Lee and D. A. Cameron (2023). "Aromatase inhibition plus/minus Src inhibitor saracatinib (AZD0530) in advanced breast cancer therapy (ARISTACAT): a randomised phase II study." Breast Cancer Research and Treatment 199(1): 35-46.
M. Tagliamento, A. Gennari, M. Lambertini, R. Salazar, N. Harbeck, L. Del Mastro, J. Aguilar-Company, M. Bower, R. Sharkey, A. Dalla Pria, A. Plaja, A. Jackson, J. Handford, A. Sita-Lumsden, C. Martinez-Vila, M. Matas, A. Miguel Rodriguez, B. Vincenzi, G. Tonini, A. Bertuzzi, J. Brunet, P. Pedrazzoli, F. D'Avanzo, F. Biello, A. Sinclair, A. J. X. Lee, S. Rossi, G. Rizzo, O. Mirallas, I. Pimentel, M. Iglesias, A. Sanchez de Torre, A. Guida, R. Berardi, A. Zambelli, C. Tondini, M. Filetti, F. Mazzoni, U. Mukherjee, N. Diamantis, A. Parisi, A. Aujayeb, A. Prat, M. Libertini, S. Grisanti, M. Rossi, F. Zoratto, D. Generali, C. Saura, G. H. Lyman, N. M. Kuderer, D. J. Pinato and A. Cortellini (2023). "Pandemic Phase-Adjusted Analysis of COVID-19 Outcomes Reveals Reduced Intrinsic Vulnerability and Substantial Vaccine Protection From Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Breast Cancer." Journal of clinical oncology : official journal of the American Society of Clinical Oncology 41(15): 2800-2814.
N. C. Turner, C. Swift, B. Jenkins, L. Kilburn, M. Coakley, M. Beaney, L. Fox, K. Goddard, I. Garcia-Murillas, P. Proszek, P. Hall, C. Harper-Wynne, T. Hickish, S. Kernaghan, I. R. Macpherson, A. F. C. Okines, C. Palmieri, S. Perry, K. Randle, C. Snowdon, H. Stobart, A. M. Wardley, D. Wheatley, S. Waters, M. C. Winter, M. Hubank, S. D. Allen and J. M. Bliss (2023). "Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer." Annals of oncology : official journal of the European Society for Medical Oncology 34(2): 200-211.
G. Velikova, J. P. Morden, J. S. Haviland, C. Emery, P. Barrett-Lee, H. Earl, D. Bloomfield, A. M. Brunt, P. Canney, R. Coleman, M. Verrill, A. Wardley, G. Bertelli, P. Ellis, R. Stein, J. M. Bliss and D. Cameron (2023). "Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer (UK TACT2; CRUK/05/19): quality of life results from a multicentre, phase 3, open-label, randomised, controlled trial." The Lancet. Oncology 24(12): 1359-1374.
N. Williams, E. M. Williams and R. Roberts (2023). "Chemotherapy induced phlebitis experienced by women with breast cancer following administration of epirubicin using a volumetric infusion pump: an observational study." European journal of oncology nursing : the official journal of European Oncology Nursing Society 64: 102322.
Conference Abstracts
D. Hanna, S. Merrick, A. Ghose, D. Yang, E. Phillips, N. R. Chopra, K. Ross, Z. Y. Boh, A. Swampillai, T. Robinson, L. Germain, C. Atkinson, A. A. Konstantis, P. Riddle, N. Cresti, J. D. Naik, A. Borley, A. Guppy, P. Schmid and M. Phillips (2023). "Real-world study of sacituzumab govitecan in metastatic triple-negative breast cancer in the United Kingdom." ESMO Open 8(1 Supplement 4): 101420.
V. G. Kaklamani, F. C. Bidard, P. Neven, A. J. Montero, M. A. Mouret-Reynier, J. Sohn, D. Taylor, F. Forget, K. K. Harnden, H. T. Khong, J. Kocsis, F. Dalenc, P. M. Dillon, S. Waters, J. A. Garcia-Saenz, P. G. Aftimos, J. Cortes, S. Scartoni, N. Habboubi and A. Bardia (2023). "Oral elacestrant vs standard-of-care in estrogen receptor-positive, HER2-negative (ER+/ HER2-) advanced or metastatic breast cancer (mBC) without detectable ESR1 mutation (EMERALD): Subgroup analysis by prior duration of CDK4/6i plus endocrine therapy (ET)." Journal of Clinical Oncology 41(16 Supplement): 1070.
A. F. C. Okines, J. Braybrooke, I. R. MacPherson, S. Sutherland, S. J. Howell, D. Wheatley, S. Waters, R. Roylance, R. D. Baird, O. Oikonomidou, C. Palmieri, M. Harries, C. Harper-Wynne, A. Sheri, S. Khan, C. Bunce, K. Mohammed, D. Lee and N. C. Turner (2023). "Randomised open-label phase II study of induction standard of care fulvestrant and CDK4/ 6 inhibition with addition of ipatasertib in metastatic ER+/HER2- breast cancer patients without circulating tumour (ct) DNA suppression (FAIM)." Journal of Clinical Oncology 41(16 Supplement): TPS1111.
X. Zhu, J. Bayani, M. Dewan, H. Tovey, L. Kilburn, K. Taylor, J. Banerji, C. Toms, A. Sadanandam, P. J. Barrett-Lee, J. Bliss, D. A. Cameron, J. M. S. Bartlett and M. C. U. Cheang (2023). "Identifying new biological subgroups of triple-negative breast cancer using next-generation integrative clustering pipeline." Annals of Oncology 34(Supplement 2): S306-S307.
Articles
O. Margalit, W. S. Harmsen, E. Shacham-Shmueli, M. M. Voss, B. Boursi, A. D. Wagner, R. Cohen, C. L. Olswold, L. B. Saltz, D. A. Goldstein, H. Hurwitz, N. C. Tebbutt, F. F. Kabbinavar, R. A. Adams, B. Chibaudel, A. Grothey, T. Yoshino, J. Zalcberg, A. de Gramont, Q. Shi and H. J. Lenz (2023). "Evaluating sex as a predictive marker for response to bevacizumab in metastatic colorectal carcinoma: Pooled analysis of 3,369 patients in the ARCAD database." European Journal of Cancer 178: 162-170.
S. M. O'Cathail, R. Adams, M. A. Hawkins, D. Sebag-Montefiore, C. A. M. Marijnen and E. Fokas (2023). "Patient-reported outcomes in PROSPECT trial (Alliance N1048) - FOLFOX is not a panacea." Clinical and Translational Radiation Oncology 43: 100672.
F.-S. Ou, D. H. Ahn, J. G. Dixon, A. Grothey, Y. Lou, P. M. Kasi, J. M. Hubbard, E. Van Cutsem, L. B. Saltz, H.-J. Schmoll, R. M. Goldberg, A. P. Venook, P. Hoff, J.-Y. Douillard, J. R. Hecht, H. Hurwitz, C. J. A. Punt, M. Koopman, C. Bokemeyer, C. S. Fuchs, E. Diaz-Rubio, N. C. Tebbutt, C. Cremolini, F. F. Kabbinavar, T. Bekaii-Saab, B. Chibaudel, T. Yoshino, J. Zalcberg, R. A. Adams, A. de Gramont and Q. Shi (2023). "Evaluation of Intratumoral Response Heterogeneity in Metastatic Colorectal Cancer and Its Impact on Patient Overall Survival: Findings from 10,551 Patients in the ARCAD Database." Cancers 15(16).
S. D. Richman, G. Hemmings, H. Roberts, N. Gallop, R. Dodds, L. Wilkinson, J. Davis, R. White, E. Yates, B. Jasani, L. Brown, T. S. Maughan, R. Butler, P. Quirke and R. Adams (2023). "FOCUS4 biomarker laboratories: from the benefits to the practical and logistical issues faced during 6 years of centralised testing." Journal of Clinical Pathology 76(8): 548-554.
E. Robinson, R. Balasubramaniam, M. Hameed, C. Clarke, S. A. Taylor, D. Tolan and K. G. Foley (2023). "Survey of rectal cancer MRI technique and reporting tumour descriptors in the UK: a multi-centre British Society of Gastrointestinal and Abdominal Radiology (BSGAR) audit." Clinical Radiology.
M. P. Saunders, R. Iype, C. Kelly, J. Crosby, R. Kerr, A. Harkin, K. Allan, J. McQueen, S. R. Pearson, J. Cassidy, L. C. Medley, S. Raouf, M. Harrison, A. Brewster, C. Rees, R. Ellis, A. L. Thomas, M. Churn, T. Iveson and N. Maka (2023). "SCOT: Tumor Sidedness and the Influence of Adjuvant Chemotherapy Duration on Disease Free Survival (DFS)." Clinical Colorectal Cancer 22(2): 231-237.
Conference Abstracts
M. Barrell, N. Abbott, R. Adams, M. Hawkins, D. Sebag-Montefiore, A. Millin and P. Wheeler (2023). "Assessing plan quality in the 'PLATO anal cancer trial 5' pilot phase with automated planning." Radiotherapy and Oncology 182(Supplement 1): S322-S323.
R. Cohen, M. Raeisi, Q. Shi, B. Chibaudel, T. Yoshino, J. R. Zalcberg, R. Adams, C. Cremolini, E. Van Cutsem, V. Heinemann, J. Tabernero, C. J. A. Punt, D. Arnold, H. I. Hurwitz, J. Y. Douillard, A. P. Venook, L. B. Saltz, T. S. Maughan, T. Andre and A. De Gramont (2023). "Prognostic value of liver metastases in colorectal cancer treated by systemic therapy: An ARCAD pooled analysis." Journal of Clinical Oncology 41(16 Supplement): 3554.
A. Gilbert, J. Webster, S. Brown, J. Copeland, S. Ruddock, D. Gilbert, M. Hawkins, R. Muirhead, A. Renehan, R. Adams, M. Harrison and D. Sebag-Montefiore (2023). "Standard vs dose reduced chemoradiotherapy in anal cancer: short-term results of the PLATO-ACT4 RCT." Radiotherapy and Oncology 182(Supplement 1): S702-S703.
S. Jones, J. Murphy, S. Gwynne, R. Adams, C. Peters, E. Hudson, J. Frost, J. Blazeby, L. Nixon, L. Batten, A. Casbard and J. Torkington (2023). "Pipac in cancers of the colon, ovary and stomach (the PICCOS trial)." Pleura and Peritoneum 8(1): A36-A37.
C. Marijnen, J. de Wilt, S. Bach, F. Peters, K. Spindler, A. Appelt, M. Teo, V. Homer, N. Abbott, I. Geh, S. Korsgen, I. Al-Najami, A. Rombouts, P. Christensen, A. Gilbert, L. Navarro-Nunez, P. Quirke, N. West and D. Sebag-Montefiore (2023). "Organ preservation in rectal cancer: the randomised STAR-TREC phase II trial." Radiotherapy and Oncology 182(Supplement 1): S207-S208.
S. M. O'Cathail, M. Qiao, R. Muirhead, R. Adams, S. Rao, K. Fisher, L. Seymour, R. Brown, T. Lille, A. Ooms, T. S. Maughan and M. A. Hawkins (2023). "A Phase 1 Trial of the Safety, Tolerability, and Biological Effects of Intravenous Enadenotucirev (EnAd), a Novel Oncolytic Virus, in Combination with Chemoradiotherapy in Locally Advanced Rectal Cancer (CEDAR)." International Journal of Radiation Oncology Biology Physics 117(2 Supplement): e329-e330.
C. S. D. Roxburgh, C. R. Hanna, J. Graham, M. P. Saunders, L. M. Samuel, N. J. M. Leod, L. Devlin, J. Edwards, L. Hillson, R. K. McMahon, L. A. Jones, C. Kelly, L. A. Lewsley, P. Morrison, P. Atherton, N. Walker, J. Gourlay, E. Tiplady, R. Adams and S. M. O'Cathail (2023). "Durvalumab (MEDI 4736) with extended neoadjuvant regimens in rectal cancer: A randomised phase II trial (PRIME-RT)." Journal of Clinical Oncology 41(4 Supplement): TPS282.
E. S. Shmueli, M. Raeisi, B. Chibaudel, H. Hurwitz, L. B. Saltz, F. F. Kabbinavar, N. C. Tebbutt, A. Grothey, R. Adams, J. R. Zalcberg, T. Yoshino, J. B. Bachet, R. Cohen, L. Sharara, T. Andre, Q. Shi and A. De Gramont (2023). "Bevacizumab in first-line therapy in lung metastases of colorectal cancer: An ARCAD pooled analysis." Journal of Clinical Oncology 41(4 Supplement): 118.
Articles
J. Morrison, P. Baldwin, L. Hanna, A. Andreou, L. Buckley, L. Durrant, K. Edey, A. Faruqi, C. Fotopoulou, R. Ganesan, K. Hillaby and A. Taylor (2024). "British Gynaecological Cancer Society (BGCS) vulval cancer guidelines: An update on recommendations for practice 2023." European Journal of Obstetrics & Gynecology and Reproductive Biology 292: 210-238.
Z. Alizzi, P. Roxburgh, D. Cartwright, A. McLaren, S. Park, R. Jones, S. Greening, E. Hudson, C. Green, S. Gray, S. Khalique, E. Karteris and M. Hall (2023). "Description of a Retrospective Cohort of Epithelial Ovarian Cancer Patients with Brain Metastases: Evaluation of the Role of PARP Inhibitors in this Setting." Journal of Clinical Medicine 12(7): 2497.
C. J. Cabasag, M. Arnold, M. Rutherford, J. Ferlay, A. Bardot, E. Morgan, J. Butler, D. L. O'Connell, G. Nelson, C. Hogdall, T. Schnack, A. Gavin, M. Elwood, L. Hanna, C. Gourley, P. De, N. Saint-Jacques, L. S. Morch, R. R. Woods, A. D. Altman, P. Sykes, P. A. Cohen, O. McNally, B. Moller, P. Walsh, D. S. Morrison, F. Bray and I. Soerjomataram (2023). "Shifting incidence and survival of epithelial ovarian cancer (1995-2014): A SurvMark-2 study." International Journal of Cancer 152(9): 1763-1777.
R. D. Morgan, A. R. Clamp, B. M. Barnes, K. Timms, H. Schlecht, L. Yarram-Smith, Y. Wallis, M. Valganon‑Petrizan, S. MacMahon, R. White, S. Morgan, S. McKenna, E. Hudson, L. Tookman, A. George, R. Manchanda, S. S. Sundar, S. Nicum, J. D. Brenton, R. S. Kristeleit, S. Banerjee, I. A. McNeish, J. A. Ledermann, S. S. Taylor, D. G. R. Evans and G. C. Jayson (2023). "Homologous recombination deficiency in newly diagnosed FIGO stage III/IV high-grade epithelial ovarian cancer: a multi-national observational study." International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 33(8): 1253-1259.
Conference Abstracts
P. Baird, E. Dyke, M. Powell, A. Taylor, L. Hanna, U. McGivern, J. Summers, A. Gore, A. Cook, J. Forrest and A. Stewart (2023). "Developing National Consensus Recommendations for Vulvar Cancer Radiotherapy Treatment." Radiotherapy and Oncology 182(Supplement 1): S20-S21.
N. Colombo, K. Harano, E. Hudson, F. Galli, Y. Antill, C. H. Choi, M. Rabaglio, F. Marme, E. Petru, C. H. Lai, E. Biagioli, L. Farinas Madrid, K. Takehara, K. Allan, Y. C. Lee, E. Piovano, C. Zamagni, G. Tasca, A. Ferrero and M. P. Barretina Ginesta (2023). "LBA40 Phase III double-blind randomized placebo controlled trial of atezolizumab in combination with carboplatin and paclitaxel in women with advanced/recurrent endometrial carcinoma." Annals of Oncology 34(Supplement 2): S1281-S1282.
N. Colombo, K. Harano, E. Hudson, F. Galli, Y. Antill, C. H. Choi, M. Rabaglio, F. Marmé, E. Petru, C. H. Lai, E. Biagioli, L. F. Madrid, K. Takehara, K. Allan, Y. C. Lee, E. Piovano, C. Zamagni, G. Tasca, A. Ferrero and M. P. B. Ginesta (2023). "Phase III double-blind randomized placebo controlled trial of atezolizumab in combination with carboplatin and paclitaxel in women with advanced/recurrent endometrial carcinoma." Annals of Oncology 34: S1281-S1282.
F. Joly, I. L. Ray-Coquard, M. J. Rubio, X. Paoletti, A. J. Davis, E. Hudson, D. Lorusso, G. Tognon, U. Hasler-Strub, C. H. Choi, M. A. Vardar, S. Lheureux, T. Van Gorp, D. S. P. Tan, F. Trillsch, L. Eberst, C. Lescure, A. C. Hardy-Bessard and M. Chaix (2023). "Randomized phase III trial in MMR deficient (MMRd) endometrial cancer (EC) patients comparing chemotherapy (CT) alone versus dostarlimab in first line advanced/metastatic setting: DOMENICA study (GINECO-EN105b/ENGOT-en13 study)." Journal of Clinical Oncology 41(16): 1.
M. McCormack, D. Gallardo Rincon, G. Eminowicz, P. Diez, L. Farrelly, C. Kent, E. Hudson, M. Panades, T. Mathews, A. Anand, M. Persic, J. Forrest, R. Bhana, N. Reed, A. Drake, H. Stobart, A. Mukhopadhyay, A. M. Hacker, A. Hackshaw and J. A. Ledermann (2023). "LBA8 A randomised phase III trial of induction chemotherapy followed by chemoradiation compared with chemoradiation alone in locally advanced cervical cancer: The GCIG INTERLACE trial." Annals of Oncology 34(Supplement 2): S1276.
Articles
J. Mathlin, N. Courtier and J. Hopkinson (2023). "Taste changes during radiotherapy for head and neck cancer." Radiography (London, England : 1995) 29(4): 746-751.
H. Mehanna, B. Carter, A. Hartley, A. K. Abou-Foul, J. Brooks, J. Jones, L. Fresco, L. Moss, T. M. Jones, S. N. Rogers and R. P. Morton (2023). "Patient preference for commonly-used, head and neck cancer-specific quality of life questionnaires in the follow-up setting (Determin): A multi-centre randomised controlled trial and mixed methods study." Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery 48(4): 613-622.
M. Mori, C. Deantoni, M. Olivieri, E. Spezi, A. Chiara, S. Baroni, M. Picchio, A. Del Vecchio, N. G. Di Muzio, C. Fiorino and I. Dell'Oca (2023). "External validation of an 18F-FDG-PET radiomic model predicting survival after radiotherapy for oropharyngeal cancer." European Journal of Nuclear Medicine and Molecular Imaging 50(5): 1329-1336.
S. Singer, A. Al-Ibraheem, M. Pinto, I. Iakovou, A. A. Osthus, E. Hammerlid, L. D. Locati, E. Gamper, J. Ignacio, S. J. Jordan, N. Kiyota, M. Buettner, D. Engesser, R. Canotilho, G. Ioannidis, O. Husson, R. R. Gama, G. Fanetti, L. Moss, J. Inhestern, G. Andry, D. Fuehrer, D. Kulis, H. Rimmele and G. Sykiotis (2023). "International Phase IV Field Study for the Reliability and Validity of the European Organisation for Research and Treatment of Cancer Thyroid Cancer Module EORTC QLQ-THY34." Thyroid : official journal of the American Thyroid Association 33(9): 1078-1089.
S. Singer, G. Sykiotis, A. Al-Ibraheem, M. Pinto, I. Iakovou, A. A. Osthus, E. Hammerlid, L. D. Locati, E. M. Gamper, J. I. Arraras, S. Jordan, M. Buettner, D. Engesser, K. Taylor, R. Canotilho, G. Ioannidis, O. Husson, R. R. Gama, G. Fanetti, L. Moss, J. Inhestern, G. Andry, H. Rimmele and N. Kiyota (2023). "The impact of electronic versus paper-based data capture on data collection logistics and on missing scores in thyroid cancer patients." Endocrine.
D. J. Thomson, C. Cruickshank, H. Baines, R. Banner, M. Beasley, G. Betts, H. Bulbeck, F. Charlwood, J. Christian, M. Clarke, O. Donnelly, B. Foran, C. Gillies, C. Griffin, J. J. Homer, J. A. Langendijk, L. W. Lee, J. Lester, M. Lowe, A. McPartlin, E. Miles, C. Nutting, N. Palaniappan, R. Prestwich, J. M. Price, C. Roberts, J. Roe, R. Shanmugasundaram, R. Simoes, A. Thompson, C. West, L. Wilson, J. Wolstenholme and E. Hall (2023). "TORPEdO: A phase III trial of intensity-modulated proton beam therapy versus intensity-modulated radiotherapy for multi-toxicity reduction in oropharyngeal cancer." Clinical and Translational Radiation Oncology 38: 147-154.
P. D. Thomson, P. N. Slevin, H. Baines, G. Betts, S. Bolton, P. M. Evans, K. Garcez, J. Irlam, L. Lee, N. Melillo, H. Mistry, E. More, P. C. Nutting, J. Price, S. Schipani, M. Sen, H. Yang and P. C. N. T. G. West (2023). "Randomised phase III trial of the hypoxia modifier nimorazole added to radiotherapy with benefit assessed in hypoxic head and neck cancers determined using a gene signature (NIMRAD)." International journal of radiation oncology, biology, physics.
J. Wadsley, G. Ainsworth, A. B. Coulson, K. Garcez, L. Moss, K. Newbold, K. Farnell, J. Swain, H. Howard, M. Beasley, A. Weaver, K. Wood, J. Marshall, M. Griffin, A. Pascoe, Y. Du, J. Taprogge, G. Flux and S. Brown (2023). "Results of the SEL-I-METRY Phase II Trial on Resensitization of Advanced Iodine Refractory Differentiated Thyroid Cancer to Radioiodine Therapy." Thyroid : official journal of the American Thyroid Association 33(9): 1119-1123.
Conference Abstracts
M. Evans, T. Rackley, S. Berenato, O. Woodley, R. Windle, R. Maggs, J. Staffurth, S. Hargreaves and P. Wheeler (2023). "Evaluation of the dosimetric impact of PET-based adaptive radiotherapy in the PEARL Clinical Trial." Radiotherapy and Oncology 182(Supplement 1): S511-S512.
E. Higgins, N. Palaniappan, R. Webster, Z. Nabi, R. Lad, K. Elliott, E. Miles, J. Canham, L. Nixon, C. Hurt, C. Heiberg, M. Beasley, T. Jones and M. Evans (2023). "Compliance to the PATHOS swallowing OAR atlas and impact on predicted dysphagia for trial patients." Radiotherapy and Oncology 182(Supplement 1): S581-S582.
G. Sykiotis, A. Al-Ibraheem, D. Engesser, M. Pinto, I. Iakovou, A. Osthus, E. Hammerlid, L. Locati, E. Gamper, J. I. Arraras, S. Jordan, N. Kiyota, M. Buttner, R. Canotilho, G. Ioannidis, O. Husson, R. Gama, G. Fanetti, L. Moss, J. Inhestern, G. Andry, D. Fuhrer, H. Rimmele and S. Singer (2023). "Predictors of poor emotional quality of life in patients with differentiated thyroid cancer – results of a prospective international study." Thyroid 33 (Supplement 1): A85-A86.
D. Thomson, N. Slevin, H. Baines, G. Betts, S. Bolton, M. Evans, K. Garcez, J. Irlam, L. Lee, N. Melillo, H. Mistry, E. More, C. Nutting, J. Price, D. Ryder, S. Schipani, M. Sen, H. Yang and C. West (2023). "Randomised phase III trial of the hypoxia modifier nimorazole added to radiotherapy with benefit assessed in hypoxic head and neck cancers determined using a gene signature (NIMRAD)." Journal of Clinical Oncology 41(16 Supplement): 6006.
F. Williams, N. Morley, D. Smith, C. Passsant, S. Quine, S. Berry, M. Doddi, D. Owens, A. Harris, T. Rackley, R. Webster, E. Evans, M. Evans and N. Palaniappan (2023). "Timing of Response Assessment PET CT in OPSCC Post Treatment and Salvage Neck Dissection Rates." Radiotherapy and Oncology 182(Supplement 1): S300.
Articles
J. D. Benitez Fuentes (2023). "The Missed Opportunity: HIV, Hepatitis C Virus (HCV), and Hepatitis B Virus (HBV) Positive Patients in Neoadjuvant and Perioperative Immunotherapy Clinical Trials for Lung Cancer." Cureus 15(12): e51265.
T. England, P. Harper, T. Crosby, D. Gartner, E. F. Arruda, K. Foley and I. Williamson (2023). "Modelling lung cancer diagnostic pathways using discrete event simulation." Journal of simulation : JOS 17(1): 94-104.
I. Fornacon-Wood, K. Banfill, S. Ahmad, A. Britten, C. Carson, N. Dorey, M. Hatton, C. Hiley, K. Thippu Jayaprakash, A. Jegannathen, A. C. Kidd, P. Koh, N. Panakis, C. Peedell, A. Peters, A. Pope, C. Powell, C. Stilwell, B. Thomas, E. Toy, K. Wicks, V. Wood, S. Yahya, G. Price and C. Faivre-Finn (2023). "Impact of the COVID-19 Pandemic on Outcomes for Patients with Lung Cancer Receiving Curative-intent Radiotherapy in the UK." Clinical oncology (Royal College of Radiologists (Great Britain)) 35(10): e593-e600.
M. G. McNamara, J. Swain, Z. Craig, R. Sharma, O. Faluyi, J. Wadsley, C. Morgan, L. R. Wall, I. Chau, N. Reed, D. Sarker, J. Margetts, D. Krell, J. Cave, S. Sothi, A. Anthoney, C. Bell, A. Patel, J. B. Oughton, D. A. Cairns, W. Mansoor, A. Lamarca, R. A. Hubner and J. W. Valle (2023). "NET-02: a randomised, non-comparative, phase II trial of nal-IRI/5-FU or docetaxel as second-line therapy in patients with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma." EClinicalMedicine 60: 102015.
Conference Abstracts
F. Blackhall, L. Moliner, A. Samson, K. Franks, I. Karydis, D. Joseph-Pietras, O. Frank, H. Lavender, M. Jannoo, M. Marshall, P. Motteram, B. J. van den Eynde, C. Leung, A. Hill, M. R. Middleton, N. A. Coupe, N. Steele, J. Spicer, P. H. Shaw and S. N. Symeonides (2023). "1502TiP A phase I/IIa trial of ChAdOx1 and MVA vaccines against MAGE-A3 and NY-ESO-1." Annals of Oncology 34(Supplement 2): S846.
R. Dodds, R. White, S. Morgan, M. Meissner, E. Waskiewicz, M. Fealey, D. Meah, R. Wardman, M. Riaz and L. Egal (2023). "Validation and implementation of a large NGS panel to test liquid biopsies from patients with suspected advanced non-small cell lung cancer (NSCLC) in an NHS genomic laboratory for the QuicDNA biomarker study." ESMO Open 8(1 Supplement 5): 101918.
D. Fennell, D. Griffiths, Z. Eminton, A. Morgan-Fox, K. Hill, T. Nearchou, L. Johnson, S. Harding, C. Poile, A. Bzura, J. Spicer, M. Nye, J. Cave, S. Danson, E. Toy, P. Jain, N. Steele, P. Shaw, P. Taylor, P. Szlosarek, D. Papadatos-Pastos, M. Lind, S. Dulloo, H. Saman, A. Bajaj, J. L. Luo, L. Darlison and G. Griffiths (2023). "Niraparib efficacy in patients with unresectable mesothelioma: a randomised phase II trial of niraparib versus active symptom control in patients with previously treated mesothelioma: NERO (TRIALS IN PROGRESS)." Lung Cancer 178(Supplement 1): S85-S86.
I. Fornacon-Wood, K. Banfill, S. Ahmad, A. Britten, C. Carson, N. Dorey, M. Hatton, C. Hiley, K. Thippu Jayaprakash, A. Jegannathen, P. Koh, N. Panakis, C. Peedell, A. Pope, C. Powell, C. Stilwell, B. Thomas, E. Toy, K. Wicks, V. Wood, S. Yahya, A. Peters, G. Price and C. Faivre-Finn (2023). "Impact of the COVID-19 pandemic on patient outcomes after curative-intent radiotherapy in the UK." Radiotherapy and Oncology 182(Supplement 1): S370-S371.
V. Gibson, V. Vigneswaran, A. Brewster, C. Powell, A. Selby, O. Nicholas, J. Flaherty, N. O'Rourke, D. Etheridge and P. Nair (2023). "Development and delivery of a second SABR service in Wales." Lung Cancer 178(Supplement 1): S18.
G. O. Griffiths, D. Griffiths, Z. Eminton, K. Hill, C. Poile, M. Nye, J. Cave, S. Danson, E. Toy, P. Jain, N. Steele, P. Shaw, P. Taylor, P. W. Szlosarek, D. Papadatos-Pastos, L. Darlison and D. A. Fennell (2023). "A randomised phase II trial of niraparib versus active symptom control in patients with previously treated mesothelioma: NERO." Journal of Clinical Oncology 41(16 Supplement): TPS8600.
A. Horne, S. Brown, V. Coyle, K. Franks, A. Hassani, S. Harrow, M. Hatton, C. Hiley, J. Kendall, J. Oughton, P. Shaw, F. Walker, H. Yang, A. Chalmers, C. Faivre-Finn and A. Greystoke (2023). "CONCORDE: a phase Ib platform study of novel agents in combination with conventional radiotherapy in NSCLC." Lung Cancer 178(Supplement 1): S86-S87.
A. Horne, S. Brown, V. Coyle, K. Franks, A. Hassani, S. Harrow, M. Hatton, C. Hiley, J. Kendall, J. B. Oughton, P. Shaw, F. Walker, H. Yang, A. J. Chalmers, C. Faivre-Finn and A. Greystoke (2023). "P2.01-04 An Update on the CONCORDE study: A Phase Ib Platform Study of Novel Agents in Combination With Conventional Radiotherapy in NSCLC." Journal of Thoracic Oncology 18(11 Supplement): S296-S297.
J. Kendall, R. H. Phillip, C. Faivre-Finn, A. Greystoke, F. Walker, J. Oughton, P. H. Shaw, C. Hiley, A. Chalmers and S. Brown (2023). "28MO Adapting the Time-to-Event Continual Reassessment Method (TiTE-CRM) to include consolidation immunotherapy in a phase I drug-radiotherapy platform trial." ESMO Open 8(1 Supplement 2): 100994.
D. Lines, K. Durno, F. Charlwood, P. Shaw, N. Lalli, V. Rompokos and C. Hiley (2023). "A comparison of proton and photon radiotherapy for treatment of malignant pleural mesothelioma." Radiotherapy and Oncology 182(Supplement 1): S1699.
M. G. McNamara, J. Swain, Z. Craig, R. Sharma, O. O. Faluyi, J. Wadsley, C. Morgan, L. R. Wall, I. Chau, N. Reed, D. Sarker, J. Margetts, D. Krell, J. Cave, S. Sharmila, A. Anthoney, A. Patel, A. Lamarca, R. Hubner and J. W. Valle (2023). "NET-02 final results: A randomised, phase II trial of liposomal irinotecan (nal-IRI)/5- fluorouracil (5-FU)/folinic acid or docetaxel as second-line (2L) therapy in patients (pts) with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (PDEP- NEC)." Journal of Clinical Oncology 41(4 Supplement): 646.
G. Middleton, P. Fletcher, J. Savage, M. Mehmi, A. Greystoke, A. Dangoor, J. Cave, C. Escriu, P. Shaw, N. Steele, P. Jain, S. Popat, M. Forster, J. Spicer, N. Coupe, S. Danson, D. Gilligan, D. Muthukumar, G. Price, Y. Summers, E. Toy and L. Billingham (2023). "MA06.06 A Phase II Trial of Ceralasertib and Durvalumab in Advanced Non-Small Cell Lung Cancer (NSCLC) with and without RAS Mutations: Results of NLMT Arm J." Journal of Thoracic Oncology 18(11 Supplement): S119-S120.
J. W. Riess, E. Cohen, J. Spicer, P. H. Shaw, J. Rubio Perez, L. Medina Rodriguez, M. F. Chaney, S. O'Neill, A. W. Pedersen, D. McDowell, E. Ehrnrooth and P. Garrido Lopez (2023). "1038P A phase II trial of the IO102-IO103 vaccine plus pembrolizumab: preliminary analysis for first-line (1L) treatment of non-small cell lung cancer (NSCLC) and squamous cell carcinoma of the head and neck (SCCHN)." Annals of Oncology 34(Supplement 2): S630.
J. W. Riess, E. Cohen, J. Vuky, P. Shaw, J. Rubio, L. M. Rodriguez, M. F. Chaney, S. O'Neill, A. Alavi, D. O. McDowell, E. Ehrnrooth and P. Garrido (2023). "MA15.09 Ph 2 Trial of IO102-IO103 Vaccine Plus Pembrolizumab: Preliminary Results for the First-line Treatment of Lung Adenocarcinoma." Journal of Thoracic Oncology 18(11 Supplement): S156.
M. Williams, S. Berenato, C. Mohler, A. Millin and P. Wheeler (2023). "Evaluation of a CT scanner based deep learning auto-contouring solution for lung radiotherapy." Radiotherapy and Oncology 182(Supplement 1): S1317-S1318.
Articles
A. Dayimu, A. Gupta, R. N. Matin, J. Nobes, R. Board, M. Payne, A. K. Rao, A. Fusi, S. Danson, B. Eccles, J. Carser, C. O. Brown, N. Steven, M. Bhattacharyya, E. Brown, M. Gonzalez, M. Highley, L. Pickering, S. Kumar, A. Waterston, G. Burghel, L. Demain, E. Baker, J. Wulff, W. D. Qian, S. Twelves, M. Middleton and P. Corrie (2024). "A randomised phase 2 study of intermittent versus continuous dosing of dabrafenib plus trametinib in patients with BRAF<SUP>V600</SUP> mutant advanced melanoma (INTERIM)." European Journal of Cancer 196: 8.
C. Bennett, S. Morgan, K. Aboud and R. D. Frazer (2023). "Use of ctDNA in identifying an actionable BRAF mutation in stage 4 metastatic melanoma." BMJ Case Reports 16(6).
A. Finall, K. Murphy and R. D. Frazer (2023). "Improving care of melanoma patients through efficient, integrated cellular-molecular pathology workflows using tissue samples with low tumour nuclear content." Journal of Clinical Pathology 76(9): 612-617.
I. Mehta, A. Dayimu, S. Kumar, C. Boobier, O. Oladipo, D. Burke, A. Olson-Brown, P. Yesildag, J. Nobes, S. Brown, C. Booth, M. Wheater, D. Muller, V. Fountain, L. Ford, R. Board, L. McGurk, S. Twelves, N. Demiris and P. Corrie (2023). "Comparison of three-weekly and six-weekly pembrolizumab United Kingdom prescribing practice for advanced and resected melanoma." European journal of cancer (Oxford, England : 1990) 194: 113344.
Conference Abstracts
H. Shaw, P. Patel, M. Payne, S. Kumar, S. Danson, M. Highley, C. Barlow, R. Miller, F. Master and L. Durrant (2023). "A DNA plasmid melanoma cancer vaccine, scib1, combined with nivolumab + ipilimumab in patients with advanced unresectable melanoma: efficacy and safety results from the open-label phase 2 scope trial." Journal for ImmunoTherapy of Cancer 11(Supplement 2): A1711.
Articles
A. Duman, O. Karakus, X. Sun, S. Thomas, J. Powell and E. Spezi (2023). "RFS+: A Clinically Adaptable and Computationally Efficient Strategy for Enhanced Brain Tumor Segmentation." Cancers 15(23).
A. Retzer, E. Baddeley, S. Sivell, H. Scott, A. Nelson, H. Bulbeck, K. Seddon, R. Grant, R. Adams, C. Watts, O. L. Aiyegbusi, P. Kearns, S. C. Rivera, L. Dirven, M. Calvert and A. Byrne (2023). "Development of a core outcome set for use in adult primary glioma phase III interventional trials: A mixed methods study." Neuro-Oncology Advances 5(1): vdad096.
H. Shuaib, G. J. Barker, P. Sasieni, E. De Vita, A. Chelliah, R. Andrei, K. Ashkan, E. Beaumont, L. Brazil, C. Rowland-Hill, Y. H. Lau, A. Luis, J. Powell, A. Swampillai, S. Tenant, S. C. Thust, S. Wastling, T. Young and T. C. Booth (2023). "Overcoming challenges of translating deep-learning models for glioblastoma: the ZGBM consortium." The British journal of radiology 96(1141): 20220206.
Conference Abstracts
K. Apostolopoulou, D. Lowes, D. Parikh, A. Mohamed, J. Maclean, N. Palaniappan and C. Hayhurst (2023). "Trigeminal neuropathy, following stereotactic radiosurgery, in patients with vestibular Schwannoma. A 5-year single-center experience." British Journal of Neurosurgery 37(5): 1447.
E. Baddeley, S. Sivell, A. Retzer, A. Nelson, H. Bulbeck, K. Seddon, R. Grant, R. Adams, C. Watts, O. Aiyegbusi, P. Kearns, S. Rivera, L. Dirven, M. Calvert and A. Byrne (2023). "Understanding the holistic needs of people living with glioma and their caregivers: a thematic analysis of the semi-structured interviews for the cobra study." Neuro-Oncology 25(Supplement 2): ii60.
E. Baddeley, S. Sivell, K. Seddon, H. Bulbeck, A. Retzer, A. Nelson, M. Calvert, R. Grant, R. Adams, C. Watts, O. Lee Aiyegbusi, S. Cruz, P. Kearns, L. Dirven and A. Byrne (2023). "Evaluation of Patient and Public Involvement in the development of a patient reported outcome set in brain tumour trials (COBra Study)." Quality of Life Research 32(Supplement 1): S16-S17.
S. J. Derby, L. Sweeting, S. Shad, L. Paterson, J. Stobo, S. Nowicki, A. Williamson, A. James, S. C. Short, C. McBain, C. Herbert, J. Powell, C. Kelly and A. J. Chalmers (2023). "Final results of the mgmt unmethylated arm of paradigm-2: a phase i study of olaparib and radiotherapy in patients with newly diagnosed glioblastoma (GBM)." Neuro-Oncology 25(Supplement 2): ii20-ii21.
A. Duman, P. Whybra, J. Powell, S. Thomas, X. Sun and E. Spezi (2023). "Transferability of deep learning models to the segmentation of gross tumour volume in brain cancer." Radiotherapy and Oncology 182(Supplement 1): S1315-S1316.
A. Retzer, E. Baddeley, S. Sivell, A. Nelson, H. Bulbeck, K. Seddon, R. Grant, R. Adams, C. Watts, O. Aiyegbusi, P. Kearns, S. Cruz Rivera, L. Dirven, M. Calvert and A. Byrne (2023). "Development of a core outcome set for use in adult primary glioma phase iii interventional trials - a mixed methods study." Neuro-Oncology 25(Supplement 2): ii58-ii59.
Articles
M. Meissner, A. Napolitano, K. Thway, P. Huang and R. L. Jones (2023). "Pharmacotherapeutic strategies for epithelioid sarcoma: are we any closer to a non-surgical cure?" Expert Opinion on Pharmacotherapy 24(12): 1395-1401.
Articles
M. E. Booth, C. M. Jones, J. Helbrow, W. Mansoor, C. J. Peters, R. D. Petty, T. J. Underwood, E. C. Smyth and T. Crosby (2023). "The UK National Oesophagogastric Multidisciplinary Team Meeting: An Initiative From the UK & Ireland Oesophagogastric Group." Clinical oncology (Royal College of Radiologists (Great Britain)) 35(7): 417-420.
A. Case, H. Hutchings, S. Prosser, G. Jenkins, T. Crosby, R. Adams and S. Gwynne (2023). "A systematic review of definitive radiotherapy for inoperable, non-metastatic gastric cancer." Radiotherapy and Oncology 182(Supplement 1): S1104-S1105.
S. D. P. Ellis, E. Kenney-Herbert, T. Crosby and S. Mukherjee (2023). "Cervical Oesophageal Cancer: A Call for Treatment Consensus." Clinical oncology (Royal College of Radiologists (Great Britain)) 35(7): 478-481.
P. Ghaneh, D. Palmer, S. Cicconi, R. Jackson, C. M. Halloran, C. Rawcliffe, R. Sripadam, S. Mukherjee, Z. Soonawalla, J. Wadsley, A. Al-Mukhtar, E. Dickson, J. Graham, L. Jiao, H. S. Wasan, I. S. Tait, A. Prachalias, P. Ross, J. W. Valle, D. A. O'Reilly, B. Al-Sarireh, S. Gwynne, I. Ahmed, K. Connolly, K. L. Yim, D. Cunningham, T. Armstrong, C. Archer, K. Roberts, Y. T. Ma, C. Springfeld, C. Tjaden, T. Hackert, M. W. Buchler and J. P. Neoptolemos (2023). "Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial." The lancet. Gastroenterology & hepatology 8(2): 157-168.
S. R. Javed, S. Lord, S. El Badri, R. Harman, J. Holmes, F. Kamzi, T. Maughan, D. McIntosh, S. Mukherjee, A. Ooms, G. Radhakrishna, P. Shaw and M. A. Hawkins (2023). "CHARIOT: a phase I study of berzosertib with chemoradiotherapy in oesophageal and other solid cancers using time to event continual reassessment method." British Journal of Cancer.
S. Mukherjee, C. N. Hurt, R. Adams, A. Bateman, K. M. Bradley, S. Bridges, S. Falk, G. Griffiths, S. Gwynne, C. M. Jones, P. J. Markham, T. Maughan, L. S. Nixon, G. Radhakrishna, R. Roy, S. Schoenbuchner, H. Sheikh, E. Spezi, M. Hawkins and T. D. L. Crosby (2023). "Efficacy of early PET-CT directed switch to carboplatin and paclitaxel based definitive chemoradiotherapy in patients with oesophageal cancer who have a poor early response to induction cisplatin and capecitabine in the UK: a multi-centre randomised controlled phase II trial." EClinicalMedicine 61: 102059.
C. J. Peters, Y. Ang, F. D. Ciccarelli, H. Coles, H. G. Coleman, G. Contino, T. Crosby, G. Devonshire, M. Eldridge, A. Freeman, N. Grehan, M. McCord, B. Nutzinger, S. Zamani, S. L. Parsons, R. Petty, A. D. Sharrocks, R. J. E. Skipworth, E. C. Smyth, I. Soomro, T. J. Underwood, P. A. W. Edwards, A. M. Redmond, C. Loreno, S. Abbas, M. O'Donovan, A. Miremadi, S. Malhotra, M. Tripathi, C. Cheah, C. Millington, M. Secrier, S. Jammula, J. Davies, C. Crichton, N. Carroll, R. H. Hardwick, P. Safranek, A. Hindmarsh, V. Sujendran, S. J. Hayes, S. R. Preston, I. Bagwan, V. Save, T. R. Hupp, J. R. O'Neill, O. Tucker, A. Beggs, P. Taniere, S. Puig, R. C. Walker, B. L. Grace, J. Lagergren, J. A. Gossage, A. R. Davies, F. Chang, U. Mahadeva, V. Goh, G. Sanders, R. Berrisford, D. Chan, E. Cheong, B. Kumar, L. Sreedharan, P. Kaye, J. H. Saunders, L. Lovat, R. Haidry, M. Scott, S. Sothi, S. Lishman, G. B. Hanna, K. Moorthy, A. Grabowska, R. C. Turkington, D. McManus, F. Bartlett and R. C. Fitzgerald (2023). "A decade of the Oesophageal Cancer Clinical and Molecular Stratification Consortium." Nature Medicine.
P. H. Pucher, M. H. Park, D. A. Cromwell, T. C. Crosby, B. Thomas, N. Trudgill, M. Wahedally, N. Maynard and J. A. Gossage (2023). "Diagnosis and treatment for gastro-oesophageal cancer in England and Wales: analysis of the National Oesophago-Gastric Cancer Audit (NOGCA) database 2012-2020." The British journal of surgery 110(6): 701-709.
S. A. Rahman, R. C. Walker, N. Maynard, N. Trudgill, T. Crosby, D. A. Cromwell and T. J. Underwood (2023). "The AUGIS Survival Predictor: Prediction of Long-Term and Conditional Survival After Esophagectomy Using Random Survival Forests." Annals of Surgery 277(2): 267-274.
J. V. Reynolds, S. R. Preston, B. O'Neill, M. A. Lowery, L. Baeksgaard, T. Crosby, M. Cunningham, S. Cuffe, G. O. Griffiths, I. Parker, S. L. Risumlund, R. Roy, S. Falk, G. B. Hanna, F. R. Bartlett, A. Alvarez‑Iglesias, M. P. Achiam, M. Nilsson, G. Piessen, N. Ravi, D. O'Toole, C. Johnston, R. S. McDermott, R. C. Turkington, S. Wahed, S. Sothi, H. Ford, M. S. Wadley and D. Power (2023).
"Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial." The lancet. Gastroenterology & hepatology 8(11): 1015-1027.
Z. C. Riddell, C. Corallo, R. Albazaz and K. G. Foley (2023). "Gallbladder polyps and adenomyomatosis." British Journal of Radiology 96(1142): 20220115.
Conference Abstracts
A. N. Case, H. Hutchings, T. Crosby, O. Nicholas, B. Thomas, C. Morgan and S. Gwynne (2023). "Gastric Radiotherapy in the UK - Current Practice and Opinion on Future Directions." International Journal of Radiation Oncology Biology Physics 117(2 Supplement): e286.
R. Evans, S. Cox, T. Crosby, J. Staffurth and S. Gwynne (2023). "SCOPE1 RTTQA - assessing adherence to tumour volume delineation guidelines." Radiotherapy and Oncology 182(Supplement 1): S2116.
J. Helbrow, J. Graby, G. Lewis, S. Cox, O. Nicholas, G. Radhakrishna, T. Crosby and S. Gwynne (2023). "Dose Escalation in Esophageal Cancer: Comparing Pre-Accrual and On-Trial Target Volume Delineation in the UK SCOPE2 Trial." International Journal of Radiation Oncology Biology Physics 117(2 Supplement): e301-e302.
J. Helbrow, O. Nicholas, G. Lewis, G. Radhakrishna, T. Crosby and S. Gwynne (2023). "Dose escalation in oesophageal cancer: comparing pre-accrual SCOPE2/PRODIGE-26 RTTQA programmes." Radiotherapy and Oncology 182(Supplement 1): S398-S399.
G. Lewis, O. Nicholas, S. Gwynne, T. Crosby, A. Chand, B. Thomas, L. Wills and G. Radhakrishna (2023). "A simplified method for delineation of target volumes in 4D oesophageal cancer radiotherapy." Radiotherapy and Oncology 182(Supplement 1): S1100-S1101.
M. G. McNamara, H. Timmins, A. Osborne, R. Cox, H. S. Wasan, P. Corrie, R. Gillmore, S. Sivakumar, Y. T. Ma, O. O. Faluyi, A. Arora, S. Arif, J. Canham, C. Hurt, R. Hubner, J. A. Bridgewater, R. Adams and J. W. Valle (2023). "ABC-12: Exploring the microbiome in patients (pts) with advanced biliary tract cancer (BTC) in a first-line study of durvalumab in combination with cisplatin/gemcitabine (cis/ gem)." Journal of Clinical Oncology 41(16): 1.
S. Mukherjee, C. Hurt, S. Gwynne, L. Nixon, S. Bridges, R. Adams, G. Radhakrishna, T. Maughan, M. Hunter, R. Kumar, R. Roy, C. Jones, C. Marshall, K. Bradley, D. Callaghan, S. Gollins, H. Sheikh, A. Bateman, S. Falk, B. Tranter, G. J. Lewis, E. Spezi, M. Hawkins and T. Crosby (2023). "SCOPE2 PET: continuing CisCap v switch to CarPac in PET non-responders on dCRT for esophageal cancer." Radiotherapy and Oncology 182(Supplement 1): S64-S65.
P. Pucher, T. Underwood, S. Kamarajah, N. Blencowe, E. Griffiths, R. Evans, S. Markar, P. Bhandari, N. Trudgill, T. Crosby and J. Gossage (2023). "Prevalence and risk factors for malignant nodal involvement in early oesophago-gastric cancer: Initial results from the CONGRESS study (endosCopic resectiON, esophaGectomy or gastrectomy foR Early oeSophagogastric cancerS)." British Journal of Surgery 110(Supplement 8): viii2.
J. V. Reynolds, S. R. Preston, B. O'Neill, M. A. Lowery, L. Baeksgaard, T. Crosby, M. Cunningham, S. Cuffe, G. O. Griffiths, R. Roy, S. Falk, G. Hanna, F. R. Bartlett, I. Parker, A. Alvarez-Iglesias, M. Nilsson, G. Piessen, S. Risum, N. Ravi and R. S. McDermott (2023). "Neo-AEGIS (Neoadjuvant Trial in Adenocarcinoma of the Esophagus and Esophago-Gastric Junction International Study): Final primary outcome analysis." Journal of Clinical Oncology 41(4 Supplement): 295.
Articles
G. Attard, L. Murphy, N. W. Clarke, A. Sachdeva, C. Jones, A. Hoyle, W. Cross, R. J. Jones, C. C. Parker, S. Gillessen, A. Cook, C. Brawley, C. Gilson, H. Rush, H. Abdel-Aty, C. L. Amos, C. Murphy, S. Chowdhury, Z. Malik, J. M. Russell, N. Parkar, C. Pugh, C. Diaz-Montana, C. Pezaro, W. Grant, H. Saxby, I. Pedley, J. M. O'Sullivan, A. Birtle, J. Gale, N. Srihari, C. Thomas, J. Tanguay, J. Wagstaff, P. Das, E. Gray, M. Alzouebi, O. Parikh, A. Robinson, A. H. Montazeri, J. Wylie, A. Zarkar, R. Cathomas, M. D. Brown, Y. Jain, D. P. Dearnaley, M. D. Mason, D. Gilbert, R. E. Langley, R. Millman, D. Matheson, M. R. Sydes, L. C. Brown, M. K. B. Parmar and N. D. James (2023). "Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol." The Lancet. Oncology 24(5): 443-456.
S. J. Crabb, S. Hussain, E. Soulis, S. Hinsley, L. Dempsey, A. Trevethan, Y. Song, J. Barber, J. Frew, J. Gale, G. Faust, S. Brock, U. McGovern, O. Parikh, D. Enting, S. Sundar, G. Ratnayake, K. Lees, A. J. Birtle, T. Powles and R. J. Jones (2023). "A Randomized, Double-Blind, Biomarker-Selected, Phase II Clinical Trial of Maintenance Poly ADP-Ribose Polymerase Inhibition With Rucaparib Following Chemotherapy for Metastatic Urothelial Carcinoma." Journal of clinical oncology : official journal of the American Society of Clinical Oncology 41(1): 54-64.
K. Fizazi, J. M. Piulats, M. N. Reaume, P. Ostler, R. McDermott, J. R. Gingerich, E. Pintus, S. S. Sridhar, R. M. Bambury, U. Emmenegger, H. Lindberg, D. Morris, F. Nole, J. Staffurth, C. Redfern, M. I. Saez, W. Abida, G. Daugaard, A. Heidenreich, L. Krieger, B. Sautois, A. Loehr, D. Despain, C. A. Heyes, S. P. Watkins, S. Chowdhury, C. J. Ryan and A. H. Bryce (2023). "Rucaparib or Physician's Choice in Metastatic Prostate Cancer." The New England journal of medicine 388(8): 719-732.
L. Garegnani, J. V. A. Franco, S. E. Melendi, R. W. M. Vernooij, J. H. Jung, E. C. Hwang, J. A. A. G. Damen, C. A. Warlick, B. Coles and P. Dahm (2023). "Prediction of disease specific and overall survival in men with prostate cancer using the Decipher assay." Cochrane Database of Systematic Reviews 2023(3): CD014746.
P. Gravestock, E. Clark, M. Morton, S. Sharma, H. Fisher, J. Walker, R. Wood, H. Hancock, N. Waugh, A. Cooper, R. Maier, J. Marshall, R. Chandler, A. Bahl, S. Crabb, S. Jain, I. Pedley, R. Jones, J. Staffurth and R. Heer (2023). "Using the AR-V7 biomarker to determine treatment in metastatic castrate resistant prostate cancer, a feasibility randomised control trial, conclusions from the VARIANT trial [version 2; peer review: 2 approved]." NIHR open research 2: 49.
R. Jones, R. Plummer, V. Moreno, L. Carter, D. Roda, E. Garralda, R. Kristeleit, D. Sarker, T. Arkenau, P. Roxburgh, H. S. Walter, S. Blagden, A. Anthoney, B. J. Klencke, M. M. Kowalski and U. Banerji (2023). "A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced Cancer." Clinical cancer research : an official journal of the American Association for Cancer Research 29(2): 331-340.
R.H. Jones, K. Fizazi, N. D. James, T. L. Tammela, N. Matsubara, F. Priou, P. Beuzeboc, T. Lesimple, P. Bono, V. Kataja, J. A. Garcia, A. Protheroe, N. Shore, J. Aspegren, H. Joensuu, I. Kuss, S. Fiala-Buskies and E. Vjaters (2023). "Safety and tolerability of long-term treatment with darolutamide in patients with metastatic castration-resistant prostate cancer." Prostate Cancer and Prostatic Diseases. Online ahead of print.
V. M. Macaulay, S. Lord, S. Hussain, J. P. Maroto, R. H. Jones, M. A. Climent, N. Cook, C.-C. Lin, S.‑S. Wang, D. Bianchini, M. Bailey, L. Schlieker, T. Bogenrieder and J. de Bono (2023). "A Phase Ib/II study of IGF-neutralising antibody xentuzumab with enzalutamide in metastatic castration-resistant prostate cancer." British Journal of Cancer 129(6): 965-973.
G. Marra, G. J. L. H. van Leenders, F. Zattoni, C. Kesch, P. Rajwa, P. Cornford, T. van der Kwast, R. C. N. van den Bergh, E. Briers, T. Van den Broeck, G. De Meerleer, M. De Santis, D. Eberli, A. Farolfi, S. Gillessen, N. Grivas, J. P. Grummet, A. M. Henry, M. Lardas, M. Lieuw, E. Linares Espinos, M. D. Mason, S. O'Hanlon, I. M. van Oort, D. E. Oprea-Lager, G. Ploussard, O. Rouviere, I. G. Schoots, J. Stranne, D. Tilki, T. Wiegel, P.-P. M. Willemse, N. Mottet and G. Gandaglia (2023). "Impact of Epithelial Histological Types, Subtypes, and Growth Patterns on Oncological Outcomes for Patients with Nonmetastatic Prostate Cancer Treated with Curative Intent: A Systematic Review." European Urology 84(1): 65-85.
C. Parker, N. Tunariu, H. Tovey, R. Alonzi, M. D. Blackledge, G. J. R. Cook, S. Chua, Y. Du, S. Hafeez, I. Murray, A. R. Padhani, J. Staffurth, A. Tree, H. Stidwill, J. Finch, A. Curcean, P. Chatfield, S. Perry, D.‑M. Koh and E. Hall (2023). "Radium-223 in metastatic castration-resistant prostate cancer: whole-body diffusion-weighted magnetic resonance imaging scanning to assess response." JNCI Cancer Spectrum 7(6).
Conference Abstracts
J. McGrane, R. Frazer, A. Bahl, D. S. Parslow, S. M. Alam, S. Nelms, A. Shaheen, A. Lydon, D. Abhi, G. Clements, H. Keenan, Y. Wang, V. Ford, A. Challapalli, A. Ferrera, S. Y. Moorcraft, W. Mohamed, E. Jones, J. K. H. Liu and G. Ratnayake (2023). "Multi-centre review of systemic anti-cancer prescribing patterns and treatment drop off rates in the United Kingdom 2018-2021." Journal of Clinical Oncology 41(6 Supplement): 689.
M. Mubarak, A. Al-Mitwalli, M. Rashid, A. Powles, J. Rees, J. Tanguay, S. Yadav, M. Jefferies, G. Kanda Swamy and K. Narahari (2023). "The role of psma pet/ct in re-staging biochemically recurrence of prostate cancer." Journal of Endoluminal Endourology 6(1): e43-e44.
M. Mubarak, A. Al-Mitwalli, M. Rashid, A. Powles, J. Rees, J. Tanguay, S. Yadav, M. Jefferies, G. Kanda Swamy and K. Narahari (2023). "PSMA PET/CT versus conventional imaging: the south welsh experience with high-risk primary prostate cancer." Journal of Endoluminal Endourology 6(1): e38-e39.
P. D. Nathan, N. Charnley, R. Frazer, J. McGrane, I. A. Muazzam, S. Rudman, A. Sharma, R. Stevenson, J. D. Hickey, A. Tahim and A. R. Ritchie (2023). "A UK real-world observational study of avelumab + axitinib (A + Ax) in advanced renal cell carcinoma (aRCC): 24-month interim results." Journal of Clinical Oncology 41(6 Supplement): 631.
I. Syndikus, C. Griffin, L. Philipps, A. Tree, V. Khoo, A. J. Birtle, A. Choudhury, C. Ferguson, J. M. O'Sullivan, M. Panades, Y. L. Rimmer, C. D. Scrase, J. Staffurth, C. Cruickshank, S. Hassan, J. Pugh, D. P. Dearnaley and E. Hall (2023). "10-Year efficacy and co-morbidity outcomes of a phase III randomised trial of conventional vs. hypofractionated high dose intensity modulated radiotherapy for prostate cancer (CHHiP; CRUK/06/016)." Journal of Clinical Oncology 41(6 Supplement): 304.
M. Williams, S. Berenato, O. Woodley, C. Mohler, E. Evans, A. Millin and P. Wheeler (2023). "Evaluation of a CT scanner based deep learning auto-contouring solution for prostate radiotherapy." Radiotherapy and Oncology 182(Supplement 1): S263-S264.
Articles
K. Aboud, M. Meissner, J. Ocen and R. Jones (2023). "Cytotoxic chemotherapy: clinical aspects." Medicine (United Kingdom) 51(1): 23-27.
J. Abraham, J. Ocen and J. Staffurth (2023). "Hormonal therapy for cancer." Medicine (United Kingdom) 51(1): 28-31.
A. E. Baggaley, G. B. R. C. Lafaurie, S. J. Tate, P. R. Boshier, S. Prosser, S. E. F. Jones, S. H. Gwynne, C. J. Peters, A. Case, A. Casbard, C. Peters, D. Chuter, E. Hudson, G. Brown, H. Hall, J. Murphy, J. Torkington, J. Parker, J. Frost, J. Garfitt, K. Perry, L. Batten, L. Nixon, P. Kyle, R. Adams, S. Jones, S. Tate, S. Kihara, A. Parker and A. Baggaley (2023). "Pressurized intraperitoneal aerosol chemotherapy (PIPAC): updated systematic review using the IDEAL framework." British Journal of Surgery 110(1): 10-18.
H. Fitzgerald and S. Kumar (2023). "Targeted agents in cancer." Medicine (United Kingdom) 51(1): 32-36.
R. Kristeleit, R. Plummer, R. Jones, L. Carter, S. Blagden, D. Sarker, T. Arkenau, T. R. J. Evans, S. Danson, S. N. Symeonides, G. J. Veal, B. J. Klencke, M. M. Kowalski and U. Banerji (2023). "A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancer." British Journal of Cancer 129(1): 38-45.
Conference Abstracts
M. H. Junejo, M. Carucci, C. Hurt, R. Adams, R. Matin, C. Proby and C. Harwood (2023). "Short sharp shock or slow burn: Clinician perspectives on treatment of actinic keratoses with 5-fluorouracil 5% cream monotherapy vs. 5-fluorouracil/calcipotriol ointment combination therapy." British Journal of Dermatology 188(Supplement 4): iv83.
Articles
E. Haire, C. Bralesford, J. Botting, E. Beasant and M. Taubert (2023). "Do not attempt cardiopulmonary resuscitation documentation: a quality improvement project." BMJ supportive & palliative care.
T. Kitson, E. Osborne, S. Noble, N. Pease, R. Alikhan, C. Bryant, T. Groves, R. Wallace, S. Walker, K. Seddon, D. Smith, L. Raisanen, J. Smith, I. Thomas, L. Upton and A. Casbard (2023). "HIDDEN2: Study protocol for the hospital deep vein thrombosis detection study in patients with cancer receiving palliative care." BMJ Open 13(9): e073049.
D. Muir, A. Johansen and F. Rawlinson (2023). "Case report: hip fracture at the end of life - guiding patients' choice of operative or nonoperative palliation." BMJ Supportive and Palliative Care 13(Supplement 3): A28.
M. Taubert (2023). "GMC investment in Nestle and McDonald's: abiding by its own rules?" BMJ (Clinical research ed.) 381: 776.
M. Taubert, B. Rose and M. Rigby (2023). "Do not attempt cardiopulmonary resuscitation decisions (DNACPR) - Policy approaches in Wales." Clinics in Integrated Care 19: 100149.
S. Tavabie, Y. Ta, E. Stewart, O. Tavabie, S. Bowers, N. White, C. Seton-Jones, S. Bass, M. Taubert, A. Berglund, S. Ford-Dunn, S. Cox and O. Minton (2023). "Seeking Excellence in End of Life Care UK (SEECare UK): a UK multi-centred service evaluation." BMJ supportive & palliative care.
Conference Abstracts
S. Gallard, F. Rawlinson, J. Hayes, E. Lang, M. Button, C. Stephenson and E. Johns (2023). "Recorded palliative care and oncology webinars: sustainable, efficient and easily accessed community education supporting the interprofessional workforce for over two years." BMJ Supportive and Palliative Care 13(Supplement 5): A49-A50.
A. Nwosu, S. Stanley, J. Norris and M. Taubert (2023). "Digital legacy and palliative care: using technology, design and healthcare partnerships to research how digital information is managed after death." BMJ Supportive and Palliative Care 13(Supplement 5): A41-A42.
M. Taubert (2023). "Palliative Care - Technology & New Media." Palliative Medicine 37(1 Supplement): 7.
Articles
D. Adjogatse, A. Michaelidou, B. Sanchez Nieto, R. Kozarski, I. Sassoon, M. Evans, T. Rackley, S. Shah, D. Eaton, L. Pike, S. Curry, S.-M. Gould, C. Thomas, A. Kong, I. Petkar, M. Reis-Ferreira, S. Connor, S. F. Barrington, M. Lei and T. Guerrero Urbano (2023). "Protocol letter: Intra-treatment Image Guided Adaptive Radiotherapy Dose-escalation Study (InGReS) - A Phase 1 multicentre feasibility study." Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 183: 109645.
I. Foster, E. Spezi and P. Wheeler (2023). "Evaluating the Use of Machine Learning to Predict Expert-Driven Pareto-Navigated Calibrations for Personalised Automated Radiotherapy Planning." Applied Sciences-Basel 13(7): 22.
F. Lacan, R. Johnston, R. Carrington, E. Spezi and P. Theobald (2023). "Towards using a multi-material, pellet-fed additive manufacturing platform to fabricate novel imaging phantoms." Journal of medical engineering & technology 47(3): 189-196.
F. Slevin, R. Rieu, M. Beasley, R. Speight, K. Aitken, J. Good, F. McDonald, T. Rackley, G. Radhakrishna, A. Haridass, L. J. Murray, A. C. Tree and A. M. Henry (2023). "Evaluation of the impact of teaching on delineation variation during a virtual stereotactic ablative radiotherapy contouring workshop." Journal of Radiotherapy in Practice 22(5): e19.
Articles
J. Bartolome, C. Molto, J. D. Benitez-Fuentes, G. Fernandez-Hinojal, A. Manzano, P. Perez-Segura, A. Mittal, F. Tamimi, E. Amir and A. Ocana (2023). "Prognostic value of human leukocyte antigen G expression in solid tumors: a systematic review and meta-analysis." Frontiers in Immunology 14: 1165813.
A. Glaviano, A. S. C. Foo, H. Y. Lam, K. C. H. Yap, W. Jacot, R. H. Jones, H. Eng, M. G. Nair, P. Makvandi, B. Geoerger, M. H. Kulke, R. D. Baird, J. S. Prabhu, D. Carbone, C. Pecoraro, D. B. L. Teh, G. Sethi, V. Cavalieri, K. H. Lin, N. R. Javidi-Sharifi, E. Toska, M. S. Davids, J. R. Brown, P. Diana, J. Stebbing, D. A. Fruman and A. P. Kumar (2023). "PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer." Molecular Cancer 22(1): 138.
S. A. McIntosh, F. Alam, L. Adams, I. S. Boon, J. Callaghan, I. Conti, E. Copson, V. Carson, M. Davidson, H. Fitzgerald, A. Gautam, C. M. Jones, S. Kargbo, G. Lakshmipathy, H. Maguire, K. McFerran, A. Mirandari, N. Moore, R. Moore, A. Murray, L. Newman, S. D. Robinson, A. Segaran, C. N. Soong, A. Walker, K. Wijayaweera, R. Atun, R. I. Cutress and M. G. Head (2023). "Global funding for cancer research between 2016 and 2020: a content analysis of public and philanthropic investments." The Lancet. Oncology 24(6): 636-645.
M. Taubert, N. White, O. Minton and P. Keeley (2023). "Speaking up at conference question and answer sessions-disruptive behaviour typography and assessment scale." Postgraduate medical journal 99(1173): 799-801.
Conference Abstracts
N. L. Abbott, A. Appelt, S. Chauvie, C. DeJean, A. Gasnier, E. Koutsouveli, A. Lisbona, M. Luzzara, L. Marcu, C. Melidis, L. N. Mazzoni, J. O’Doherty, R. Wientje and C. Rønn Hansen (2023). "The role of medical physicists in clinical trials across Europe." Radiotherapy and Oncology 182(Supplement 1): S8-S9.
The following appendix lists the Publications from 2023 for the Welsh Blood Service. This listing has been complied the Velindre University NHS Trust's Library Service.
During 2023, there has been a total of 31 publications - 11 articles and 20 conference abstracts. There has also been 5 theses, 1 magazine article and 2 national guidance pieces.
T. O. Apelseth, B. Doyle, R. Evans, C. George, C. Humbrecht, T. Klei, T. Najdovski, O. E. Sigurjonsson, M. Wiltshire and D. de Korte (2023). "Current transfusion practice and need for new blood products to ensure blood supply for patients with major hemorrhage in Europe." Transfusion 63(S3): S105-S111.
R. Battle, D. Pritchard, S. Peacock, C. Hastie, J. Worthington, S. Jordan, J. A. McCaughlan, M. Barnardo, R. Cope, C. Collins, N. Diaz-Burlinson, C. Rosser, L. Foster, D. Kallon, O. Shaw, D. Briggs, D. Turner, A. Anand, A. Akbarzad-Yousefi and D. Sage (2023). "BSHI and BTS UK guideline on the detection of alloantibodies in solid organ (and islet) transplantation." International Journal of Immunogenetics 50(S2): 3-63.
A. De'Ath, M. T. Rees and D. Pritchard (2023). "The history and evolution of HLA typing external proficiency testing schemes in UK NEQAS for H&I." Frontiers in Genetics 14: 1272618.
C. E. George, S. Grimsley, R. Cumber, N. Thornton, H. Davies, C. Harris, E. Massey and K. Perera (2023). "Transfusion of incompatible blood to a patient with alloanti-Sc1." Immunohematology 39(2): 70-71.
C. E. George, C. V. Saunders, A. Morrison, T. Scorer, S. Jones and N. C. Dempsey (2023). "Cold stored platelets in the management of bleeding: is it about bioenergetics?" Platelets 34(1): 2188969.
S. Harker, S. E. James, J. Murphy, B. Davies, C. Moore, B. P. Tennant, J. Geen and D. Thomas (2023). "Serosurveillance of SARS-CoV-2 in Welsh Blood Donors: Establishment of the surveillance system and results up to November 2022." Eurosurveillance 28(19): 2200473.
T. R. L. Klei, S. Begue, A. Lotens, O. E. Sigurjonsson, M. D. Wiltshire, C. George, P. J. M. van den Burg, R. Evans, L. Larsson, S. Thomas, T. Najdovski, W. Handke, J. Eronen, B. Mallas and D. de Korte (2023). "Recommendations for in vitro evaluation of blood components collected, prepared and stored in non-DEHP medical devices." Vox Sanguinis 118(2): 165-177.
J. Nash, A. Davies, C. V. Saunders, C. E. George, J. O. Williams and P. E. James (2023). "Quantitative increases of extracellular vesicles in prolonged cold storage of platelets increases the potential to enhance fibrin clot formation." Transfusion Medicine 33(6): 467-477.
J. Nash, C. V. Saunders and C. George (2023). "pH is unsuitable as a quality control marker in platelet concentrates stored in platelet additive solutions." Vox Sanguinis 118(3): 183-184.
D. Pritchard, A. Anand, A. De'Ath, H. Lee and M. T. Rees (2023). "UK NEQAS and BSHI guideline: Laboratory testing and clinical interpretation of HLA genotyping results supporting the diagnosis of coeliac disease." International Journal of Immunogenetics. Epub 2023 Dec 28.
S. Thomas, B. Roberts, D. Domanovic, K. Kramer, D. Klochkov, S. Sivasubramaniyam, D. Miloslavich, J. P. Plancon, F. Rossi, D. Misztela, L. Kirkpatrick, G. Miflin, J. Birchall, L. McLintock and R. Knight (2023). "Safety profile of plasma for fractionation donated in the United Kingdom, with respect to variant Creutzfeldt-Jakob disease." Vox Sanguinis 118(5): 345-353.
A. Cleaton, E. Burrows, K. Robinson, M. Richardson, D. Pritchard, T. Rees (2023) “The Impact of COVID-19 Infection on HLA Antibody Profiles” International Journal of Immunogenetics, 50, (Supplement 1) P1.
A. De’Ath, D. Pritchard, T. Rees (2023) “Performance of UK and Ireland Laboratories in UK NEQAS for H&I Crossmatching Schemes Over the Last 5 Years” International Journal of Immunogenetics, 50, (Supplement 1) P17.
A. De'Ath, G. Clarke, D. Pritchard and T. Rees (2023). "Comparison of kit use and performance in UK NEQAS for H&I Scheme 3-HLA antibody specificity analysis." HLA 101(4): 386.
A. Harris and S. Davies (2023) “Influencing First Time Donors to Return” Vox Sanguinis 118 (Supplement 1) P96.
A. Jones and L. Wong. (2023) “The All-Wales transfusion record: A re-design for life-saving best practice” Transfusion Medicine 33, (Supplement 1) PO64.
C. George, H. Davies, G. Nottage, J. Spittje, E. Donk, S James (2023) Evaluation of a novel monoclonal anti-Vel phenotyping reagent. Vox Sanguinis 118 (Supplement 1) P284.
C. Reilly-Stitt, I. Jennings, S. Kitchen, C. Saunders, C. George and T. Scorer (2023). "NEQAS BC and WBS use cold-stored platelets to launch EQA programme for light transmission aggregometry." British Journal of Haematology 201(Supplement 1): 51.
C. Reilly-Stitt, M. Cahillane, C. Saunders, C. George, T. Scorer, I. Jennings, S. Kitchen and I. Walker (2023). "NEQAS BC launches external quality assessment for light transmission aggregometry (LTA) using cold stored platelet concentrates." Haemophilia 29(Supplement 1): 179.
D. Pritchard (2023) “Improving the Laboratory Turnaround Time for Live Kidney Donor Transplant Compatibility Testing” International Journal of Immunogenetics, 50, (Supplement 1) P11.
F. May, S. Griffin, M. Menon, T. Hussell, T. Rees (2023) “Immune Profiles Associated with Response to Desensitisation and Clinical Outcome in Renal Transplantation” International Journal of Immunogenetics, 50, (Supplement 1) O13.
J. Gregory (2023) “Developing a collaborative national blood transfusion training package for student nurses in Wales” Royal Collage of Nursing Education Forum National Conference & Exhibition.
J. Nash, A. Davies, C. Saunders, C. George, J.O. Williams, P.E. James (2023) “Extracellular vesicles: A key consideration for future studies.” Transfusion Medicine 33, (Supplement 1) PO15.
L. Wong, J. Neville, D. Underwood, H. Dodampegamage. (2023) “Using Microsoft office forms to support infectious disease look back processes” Transfusion Medicine 33, (Supplement 1) PO92.
M. Cahillane, N. Pearce, N. Polidano, C. Saunders, L. Paletto, C. George. (2023) “The development of a novel x3 buffy coat derived pooled platelet component through data modelling of current manufacturing processes. Transfusion Medicine 33, (Supplement 1) PO14.
M. Hazell, N. Wilkes, L. Eastwood, T. Bullock, S. Reynolds, A. Hogan, A. Muir, M. O'Shea, J. McCullagh, C. George, S. Grimsley, S. Wright. (2023) “One size doesn't fit all–Mapping of the journey related to the transfusion science higher specialist scientific training. Transfusion Medicine 33, (Supplement 1) PO55.
N. Pearce, C. Saunders, A. Mohamed and C. George (2023). “Effect of mixing on the quality of red cells at time expiry.” Transfusion Medicine 33, (Supplement 1) PO10.
N. Wilkes, L. Eastwood, T.Bullock, S. Grimsley, S. Wright, C. George, J. McCullagh, A. Muir, M. O'Shea, S. Reynolds, M. Hazell (2023) “Transfusion revision recipe for success” Transfusion Medicine 33, (Supplement 1) PO48.
R. Stevens and F. May (2023) “The ‘Kidney Transplant Dashboard’ International Journal of Immunogenetics, 50, (Supplement 1) P4.
S. Ditcham (2023) “Delivering a National perioperative Anaemia Pathway – Utilising laboratory services to drive clinical improvement” The Royal College of Pathologists Wales Symposium 2023.
S. Ditcham, J. Gregory, C. Jones, K. Towell, L. Wong, C. Evans. (2023) “Perioperative anaemia pathway in Wales revisited–The next steps to achieving implementation.” Transfusion Medicine 33, (Supplement 1) PO74.
L. Oates (2023) Determining a threshold for listing of HLA-DQ unacceptable antigens: The association between Luminex® MFI value and flow cytometry crossmatch results. British Society for Histocompatibility and Immunogenetics Diploma. 2023.
L. Paletto (2023) Evaluation of High Titre buffy coat status on the High Titre Haemolysis Status of Platelet Pools in Platelet Additive Solution. Cardiff Metropolitan University
A. Paramore (2023) The effect of digital technology on blood donor engagement and its impact on levels of engagement in Wales donor engagement and its impact on levels of engagement in Wales. University of South Wales
M. Cahillane (2023) Use of Global Haemostasis Assays for the Evaluation of Thawed Plasma for Clinical Use. University of West of England
A. Brick (2023) Titre scores: An alternative to continuous flow analysis for monitoring antenatal patients in the Welsh Blood Service? University of West of England
V. Binding, C. Hughes, L. Kadelka-Williams, J. Hughes (2023) Next Gen Scientists: Navigating the Differing Routes to Registration. Bloodlines Issue 146, September 2023 (British Blood Transfusion Society)
A. Jones (2023) United Kingdom and Ireland Blood Transfusion Network: Consent for Blood Transfusion - Guidance for Healthcare Practitioners in the UK
J. Gregory (2023) United Kingdom and Ireland Blood Transfusion Network: Transfusion Information for Patients